Background
==========

The radiolabelled inhibitor of the multidrug efflux transporter P-glycoprotein (P-gp) \[^11^C\]elacridar was developed as a positron emission tomography (PET) tracer to assess expression levels of P-gp at the blood-brain barrier (BBB) \[[@B1]\]. \[^11^C\]Elacridar was shown to interact specifically with P-gp at the rodent BBB, but its brain PET signal was very low, which was possibly caused by transport of \[^11^C\]elacridar by P-gp \[[@B1]\]. In an attempt to gain a better understanding of the required properties of an effective P-gp PET tracer we evaluated ^11^C-labelled MC113, a structural analogue of elacridar, which was characterised as an unambiguous non-transported P-gp inhibitor and which possesses lower molecular weight, lower lipophilicity and higher potency for P-gp inhibition than elacridar (EC~50~ for inhibition of \[^3^H\]vinblastine transport in Caco-2 cell monolayers: 0.6 µM vs. 2.0 µM for elacridar) \[[@B2]\].

Methods
=======

Female wild-type (n = 3) and Mdr1a/b^−/−^ (n = 2) mice (Taconic Inc., USA) underwent paired PET scans with \[^11^C\]MC113 using a microPET Focus220 scanner (Siemens, Medical Solutions, USA). A baseline scan (150 min), during which the P-gp inhibitor tariquidar (15 mg/kg) was administered i.v. at 60 min after radiotracer injection, was followed by a second 60-min scan at 2 h after administration of tariquidar. Whole-brain time-activity curves were calculated using the image analysis software Amide.

Results
=======

\[^11^C\]MC113 was evaluated using an identical set-up which we had previously used for \[^11^C\]elacridar and which employed a combination of chemical and genetic knockout of P-gp \[[@B1]\]. \[^11^C\]MC113 had a 3 times higher peak brain activity uptake than \[^11^C\]elacridar, but otherwise behaved identically to \[^11^C\]elacridar, in that brain activity uptake was higher in Mdr1a/b^−/−^ than in wild-type mice and that inhibitor administration increased brain activity uptake in wild-type mice. However, the observed effects were smaller for \[^11^C\]MC113 than for \[^11^C\]elacridar.

Conclusions
===========

Our data suggest that \[^11^C\]MC113 interacts with P-gp at the murine blood-brain barrier, but as for \[^11^C\]elacridar its *in vivo* behaviour points to transport by P-gp. The higher brain activity uptake of \[^11^C\]MC113 might be an advantage over \[^11^C\]elacridar for PET imaging of P-gp.
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